Parents of a Child With Familial Chylomicronemia Syndrome Advocate for Passing the HEART Act
source: pixabay.com

Parents of a Child With Familial Chylomicronemia Syndrome Advocate for Passing the HEART Act

According to an article in the Times Union, a group of parents with children who have been diagnosed with rare diseases are leading the crusade to foster federal legislation which…

Continue Reading Parents of a Child With Familial Chylomicronemia Syndrome Advocate for Passing the HEART Act
RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community
source: pixabay.com

RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community

On October 15th, 2020, the Rare Disease Legislative Advocates (RDLA) held a webinar discussing some of the latest news regarding ongoing legislation that is most relevant to the rare disease…

Continue Reading RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community
Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act
https://pixabay.com/en/book-book-gift-heart-gift-read-1760998/

Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act

  In a July 9 press release, the Familial Chylomicronemia Syndrome (FCS) Foundation announced its support for a bill introduced by Congressman Paul Tonko (D-NY) and David B. McKinley (R-WV).…

Continue Reading Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act
ICYMI: Successful Phase 3 Study of Familial Chylomicronemia Syndrome Drug May Win Drug Approval in US
TeroVesalainen / Pixabay

ICYMI: Successful Phase 3 Study of Familial Chylomicronemia Syndrome Drug May Win Drug Approval in US

According to a publication from BioPortfolio, American biotechnology companies Akcea Therapeutics and Ionis Pharmaceuticals recently published final study results from their phase 3 clinical study of Waylivra (generic name volanesorsen)…

Continue Reading ICYMI: Successful Phase 3 Study of Familial Chylomicronemia Syndrome Drug May Win Drug Approval in US

A Potential Treatment for Familial Chylomicronemia Syndrome Performs Well in Trials

According to a story from EurekAlert!, the results of a recent clinical trial should get the attention of patients in the US with the rare disorder familial chylomicronemia syndrome. The…

Continue Reading A Potential Treatment for Familial Chylomicronemia Syndrome Performs Well in Trials

Study has Commenced for a New Potential Familial Chylomicronemia Syndrome Treatment

Hypertriglyceridemia Hypertriglyceridemia is the term used to describe abnormally high numbers of triglycerides in the blood. People with Hypertriglyceridemia have an increased risk of heart disease, stroke, and heart attack.…

Continue Reading Study has Commenced for a New Potential Familial Chylomicronemia Syndrome Treatment

New Treatment for Familial Chylomicronemia Syndrome is Close to Approval in the EU

Familial Chylomicronemia Syndrome Familial chylomicronemia syndrome (FCS) is a condition that is considered ultra-rare. It's caused when the enzyme called lipoprotein lipase (LPL) is impaired. It is can result in…

Continue Reading New Treatment for Familial Chylomicronemia Syndrome is Close to Approval in the EU
Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome
source: pixabay.com

Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome (FCS) Is a rare disease caused by malfunctioning lipoprotein lipase. This results in a buildup of triglycerides in the body's plasma. FCS can cause pancreatitis, memory loss, nerve…

Continue Reading Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome
ICYMI: After Rejection, The Familial Chylomicronemia Foundation Urges The FDA to Consider Approving New Treatment
www_slon_pics / Pixabay

ICYMI: After Rejection, The Familial Chylomicronemia Foundation Urges The FDA to Consider Approving New Treatment

According to a story from BioSpace, the U.S. Food and Drug Administration (FDA) recently rejected the approval of the drug Waylivra, which was in development for the treatment of familial…

Continue Reading ICYMI: After Rejection, The Familial Chylomicronemia Foundation Urges The FDA to Consider Approving New Treatment

Results from First Study on Patient-To-Patient Connectivity in Those with FCS

  According to DAIC, Akcea Therapeutics Inc., has recently announced their publication of results from their study analyzing patient-to-patient connectivity towards the management of the rare disease familial chylomicronemia syndrome (FCS).…

Continue Reading Results from First Study on Patient-To-Patient Connectivity in Those with FCS
Treatment for Familial Chylomicronemia Syndrome Gets Recommendation From FDA Committee
source: pixabay.com

Treatment for Familial Chylomicronemia Syndrome Gets Recommendation From FDA Committee

According to a story from cafepharma.com, Akcea Therapeutics, Inc. recently announced that the FDA's Division of Metabolism and Endocrinology Products Advisory Committee voted to recommend approval of the therapy Waylivra…

Continue Reading Treatment for Familial Chylomicronemia Syndrome Gets Recommendation From FDA Committee
Gene Therapy Appears Effective for Familial Chylomicronemia Syndrome
source: pixabay.com

Gene Therapy Appears Effective for Familial Chylomicronemia Syndrome

According to a story from eurekalert.org, the first patient that received treatment with alipogene tiparovovec reported positive results after an eighteen month treatment period. Alipogene tiparovovec is a gene therapy…

Continue Reading Gene Therapy Appears Effective for Familial Chylomicronemia Syndrome
Communicating and Connecting With Others Can Improve Quality of Life in FCS Patients
source: pixabay.com

Communicating and Connecting With Others Can Improve Quality of Life in FCS Patients

According to a story from the Rare Disease Report, the results of a recent survey questionnaire indicate that communicating with other rare disease patients can cause a significant improvement in…

Continue Reading Communicating and Connecting With Others Can Improve Quality of Life in FCS Patients
Global Genes Highlights Firefighter Experience with Familial Chylomicronemia Syndrome
felljagd3150 / Pixabay

Global Genes Highlights Firefighter Experience with Familial Chylomicronemia Syndrome

Severe diarrhea. Daily abdominal pain. Extremely high triglycerides. Chronic pancreatitis. Joint pain. Incredibly uncomfortable conditions for anyone. Now imagine you’ve experienced this pain your entire life without knowing what was…

Continue Reading Global Genes Highlights Firefighter Experience with Familial Chylomicronemia Syndrome